Canada: Supreme Court Of Canada Redefines Law On Anticipation And Obviousness

Copyright 2008, Blake, Cassels & Graydon LLP

Originally published in Blakes Bulletin on Intellectual Property, November 2008


On November 6, 2008, the Supreme Court released its decision in Apotex Inc. v. Sanofi-Synthelabo Canada Inc. The primary issue before the court was the validity of selection patents. In its decision, the court upheld the validity of such patents and also established new guidelines for assessing anticipation and obviousness of patent claims.

Selection patents are directed to a specific subset or species of a known class or genus. Patents of this sort are common in, but not exclusive to, the chemical and pharmaceutical fields where a particular compound or a related set of compounds (i.e., a species) within a known class (i.e., genus) are found to have certain significant advantages over other members of the class.

Sanofi-Synthelabo Canada Inc. (Sanofi) is the owner of patent number 1,336,777 ('777) and its predecessor, patent number 1,194,875 ('875). The '777 patent is directed to clopidogrel bisulfate, which is an anti-coagulant marketed by Sanofi under the trade name Plavix. The '875 patent discloses a large genus of related compounds, including a racemate comprising clopidogrel bisulfate as well as its levo-rotatory (L) isomer. In the course of its investigation, Sanofi determined that the D isomer – clopidogrel bisulfate – exhibited higher effectiveness and lower toxicity as compared to the L isomer and the racemate, and obtained the '777 patent on this basis.

Apotex sought a Notice of Compliance (NOC) to market a generic version of clopidogrel bisulfate and, in so doing, challenged the validity of the '777 patent on various grounds including anticipation and obviousness based on the prior '875 patent. The lower courts upheld the validity of the '777 patent and Apotex appealed to the Supreme Court.

The Decision

Selection Patents

In its decision, the court first concluded that selection patents are valid in principle. The court went on to set out the following three-part test for establishing the validity of selection patents:

1. The selected members must provide some substantial advantage (or avoid some disadvantage).

2. The whole of the selected members (subject to "a few exceptions here and there") must possess the advantage in question.

3. The selection must be in respect of a quality or a special character peculiar to the selected group.

On the evidence, the court found the '777 patent to meet these criteria. In this regard, the court highlighted the high effectiveness of clopidogrel bisulfate and the reduced toxicity as compared to its L isomer or the known racemate.


Although the conditions for novelty are set forth in the Patent Act, the 1986 Federal Court of Appeal decision in Beloit Canada Ltd. v. Valmet Oy established the so-called "Beloit" test for determining anticipation. This test requires the finding of anticipation to be based on whether a single prior publication provides clear direction to a person skilled in the art to be lead to the claimed invention.

In the present case, the Supreme Court has deemed the Beloit test to be only the first step in an anticipation analysis. Specifically, the court held that anticipation requires two criteria: 1) disclosure and 2) enablement. The court explained that the Beloit test establishes only the first criterion, namely that the prior art reference must provide a disclosure of the claimed invention. However, the second criterion, namely, that of enablement requires that such disclosure must have been sufficient to enable a person skilled in the art to perform or make the claimed invention without "undue burden". In establishing this two-part anticipation test, the court recognized that, with respect to the enablement requirement, some use of "common general knowledge" and a "normal" amount of experimentation may be permissible.

In its decision, the court appears to have raised the threshold for determining anticipation by introducing the enablement requirement.

Nevertheless, after establishing and applying the two-part anticipation test, the court held that neither criterion was met by Apotex and, in the result, found the '777 patent to be novel over the prior '875 patent.


The test for obviousness also stems from the aforementioned Beloit decision, which stated that for a claim to be found obvious, a person skilled in the art and having common general knowledge must have come directly and without difficulty to the invention. In the present decision, the Supreme Court held that the Beloit test for obviousness has been interpreted too restrictively in Canada and that such definition needed to be re-examined in view of recent U.K. and U.S. law. In this analysis, the court referred to the recent KSR decision by the U.S. Supreme Court.

In its decision, the court has established a refined test for obviousness and determined that an obviousness inquiry should comprise the following four steps:

1. Identification of the relevant "person skilled in the art" and the common general knowledge that such person would have.

2. Construction of the claims in question to identify the inventive concept.

3. Identification of the differences between the construed claim and the prior art.

4. Determination of whether such differences would have been obvious to the person skilled in the art or whether they require a degree of inventiveness.

The above criteria are essentially similar to the Beloit test for obviousness. However, the court further clarified that in some instances, such as where an invention was arrived at after experimentation (as in the case in question), the last step may also involve an assessment of whether the invention was "obvious to try". In summary, the court identified at least the following four factors that may, depending on the facts, be considered in determining whether an invention was "obvious to try":

1. Is it more or less self-evident that what is being tried ought to work? That is, are there a finite number of predictable solutions that will be known to persons skilled in the art?

2. What is the nature and amount of effort required to achieve the invention? Would such effort require routine trials or prolonged experimentation?

3. Is there a motive provided in the prior art to find the solution addressed by the patent?

4. What was the course of conduct that was followed in arriving at the invention? That is, was the invention arrived at quickly and easily in view of the prior art and common general knowledge or did it involve a level of effort or knowledge above that of a skilled person?

With regard to obviousness, the court has arguably lowered the threshold by introducing an "obvious to try" test for determining inventive step. This notwithstanding, after analysing the facts and the claims of the '777 in light of the above criteria, the court found that such claims were not obvious in view of the prior '875 patent.


In this decision, the Supreme Court has provided guidance on a number of issues. First, the court has clarified the validity of selection patents by finding that where a selection, or species, is shown to have a "substantial" advantage over a known genus, it would, subject to other tests of validity, constitute patentable subject matter.

Second, the court has provided additional criteria for determining anticipation and obviousness. A new two-part test for anticipation has been proposed wherein a criterion of enablement has been added. The court has also arguably broadened the definition of obviousness by introducing an "obvious to try" criterion. As indicated above, the court has deemed the previous Beloit obviousness test to be to restrictive and has sought to bring the interpretation of obviousness in Canada in line with that of the United Kingdom and the United States.

It remains to be seen how this decision will be applied by the Canadian courts and the Canadian Intellectual Property Office.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
16 Oct 2018, Seminar, Toronto, Canada

Join Blakes lawyers for our 10th annual overview of recent legal and regulatory developments and practical strategies to navigate the changing regulation of Canada’s payments industry.

26 Oct 2018, Other, Vancouver, Canada

Cybersecurity, including data privacy and security obligations, has become a critical chapter in every company’s risk management playbook.

30 Oct 2018, Other, Toronto, Canada

Please join us for discussions on recent updates and legal developments in pension and employee benefits as well as employment law issues.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions